Issues
-
Cover Image
Cover Image
Multiplex immunofluorescence (mIF) is a powerful technology that enables visualization of the spatial relationships between cells in the tumor microenvironment (TME). Using tumor tissue from 93 patients with metastatic melanoma, Giraldo et al. developed and validated a mIF data-analysis pipeline and spatial uniform manifold approximation and projection (UMAP) algorithm to cluster and visualize the data. This approach revealed that PD-L1 and PD-1 expression intensity was spatially encoded in the TME. For example, PD-L1 expression intensity was highest on CD163+ cells in neighborhoods with a high density of CD8+ cells. The differences in spatial clustering correlated with distinct clinical outcomes, highlighting the potential for using this approach to identify prognostic and predictive immuno-oncology biomarkers. Read more in this issue on page 1262. Original image from Fig. 1B. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We’re Reading
Obituary
Commentary
Supporting the Next Generation of Scientists to Lead Cancer Immunology Research
Review
Priority Brief
Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery
Research Articles
The Fibronectin–ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells
In this study, the fibronectin–ILT3 interaction is shown to represent a “stromal checkpoint” through which the extracellular matrix actively suppresses tumor-associated myeloid cells. Therapeutics targeting this interaction can potentially reprogram suppressive myeloid cells, increasing antitumor immune responses.
Targeting the Atf7ip–Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity
Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade
Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients
CD8+ T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA PVT1
β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.